Phase II study of pegylated liposomal doxorubicin (Caelyx) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy.
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2012
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- Acronyms AROBASE
- 04 Jul 2012 Merck and Co added as associations as reported in the European Clinical Trials Database record.
- 10 Aug 2011 New trial record